Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892761 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4892769 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4888067 | 0.87 | HTR2C (0.48) | HTR2CHTR2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4888076 | 0.87 | HTR2C (0.48) | HTR2CHTR2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4888083 | 0.87 | HTR2C (0.48) | HTR2CHTR2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4889713 | 0.86 | HTR2C (0.43) | SLC6A2SLC6A4HTR2CHTR2ACHRNB2 | |
| SCHEMBL4889691 | 0.86 | HTR2C (0.43) | SLC6A2SLC6A4HTR2CHTR2ACHRNB2 | |
| SCHEMBL4889706 | 0.86 | HTR2C (0.43) | SLC6A2SLC6A4HTR2CHTR2ACHRNB2 | |
| SCHEMBL4885065 | 0.84 | EPHX2 (0.46) | HTR2CHTR2A | |
| SCHEMBL4885060 | 0.84 | EPHX2 (0.46) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | SLC6A2 1043/4885SLC6A4 719/4885SLC6A3 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.